

# Market Analysis


Ebrahim S. Mohammadi\*



## Regional Analysis

Diabetes is a genuine chronic disease that happens either when the pancreas does not create enough insulin or then again when the body can't viably utilize the insulin it produces. Diabetes is a significant public medical issue, one of the four pre-eminent noncommunicable diseases. The prevalence of diabetes have been relentlessly expanding in the past few years.

In 2011 it is found that in the case of diabetes patients a crude prevalence of 8.38% was seen in Germany. The most prevalence was found in the east German states with 12.74% and the lowest was in northmost states with 6.05%. Men has higher prevalence with 8.84% than women, who has 7.98%. In 2022, it is predicted that the total prevalence will amount to 9.34%.




The experts from the scientific field of Diabetes and Endocrinology are honoured with various awards in the conference for their contributions and research works. The awards are presented to the conference

attendees with an intent to encourage their research spirit and improve their dedication. Perceiving

Major Diabetes and Endocrinology Associations in Germany:

- Boehringer Ingelheim Pharmaceutical company, Germany
- Merck Group Pharmaceutical, Chemical and Life Science company, Germany
- Diabetic Centre Margentheim Modern treatment Centre for Diabetes Mellitus, Germany
- Bürger hospital Frankfurt Diabetes Clinic, Germany
- Asklepios Clinic Birkenwerder Diabetes Clinic, Germany
- Diabetes-Centre Bad Lauterberg Diabetes Clinic, Germany
- Diabetes-Clinic Bad Nauheim, Germany



## World Analysis

As indicated by the International diabetes Federation (IDF) insights, currently every seven seconds someone is reckoned to die from diabetes or by its complications. 50% of the deaths are happening mostly under the age of 60 years. Diabetes prevalence has been risen more rapidly in the developing countries. By the year of 2045, the Diabetes is expected to increase further to 9.9% globally. This counts a population of 424.9 million people with diabetes in 2017 will extend to 48% which will be around 628.6 million people. Practically 50% of the deaths from Hyperglycaemia happen before the age of 70 years. World Health Organization (WHO) calculated that Diabetes is the seventh leading cause of death in 2016.

## Economic Impact

Diabetes forces an enormous financial loss on the world healthcare system and the global economy. This burden can be measured through direct medical costs and indirect cost related to productivity loss which effects the Gross Domestic Product (GDP) as well. Studies show that losses in global GDP from 2011 to 2030, contain both the direct and indirect cost of diabetes will add up to 1.7 trillion dollars involving 900 billion dollars for high-pay nations and 800 billion dollar

Diabetologist, Hamadan University, Iran

\*Author for correspondence: Ebrahim.S.Mohammadi@gmail.com